Development of Molecularly Targeted Therapies to Treat Pediatric Malignancies

Drugs and biologics developed to treat children with cancer have been historically developed in adults for adult indications. Although leading to many useful drugs and biologics to treat pediatric cancer, future development of molecularly targeted therapies (MTTs) should be directed toward pediatric...

Descripción completa

Detalles Bibliográficos
Autores principales: Stewart, Clinton F., Robinson, Giles W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Development
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5656826/
https://www.ncbi.nlm.nih.gov/pubmed/28836264
http://dx.doi.org/10.1002/cpt.785
_version_ 1783273773315653632
author Stewart, Clinton F.
Robinson, Giles W.
author_facet Stewart, Clinton F.
Robinson, Giles W.
author_sort Stewart, Clinton F.
collection PubMed
description Drugs and biologics developed to treat children with cancer have been historically developed in adults for adult indications. Although leading to many useful drugs and biologics to treat pediatric cancer, future development of molecularly targeted therapies (MTTs) should be directed toward pediatric tumors more specifically to maximize antitumor efficacy while minimizing acute morbidity and long‐term disability. This will put pediatric clinicians closer to the goal of cure for all children diagnosed with cancer.
format Online
Article
Text
id pubmed-5656826
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-56568262017-10-27 Development of Molecularly Targeted Therapies to Treat Pediatric Malignancies Stewart, Clinton F. Robinson, Giles W. Clin Pharmacol Ther Development Drugs and biologics developed to treat children with cancer have been historically developed in adults for adult indications. Although leading to many useful drugs and biologics to treat pediatric cancer, future development of molecularly targeted therapies (MTTs) should be directed toward pediatric tumors more specifically to maximize antitumor efficacy while minimizing acute morbidity and long‐term disability. This will put pediatric clinicians closer to the goal of cure for all children diagnosed with cancer. John Wiley and Sons Inc. 2017-08-24 2017-11 /pmc/articles/PMC5656826/ /pubmed/28836264 http://dx.doi.org/10.1002/cpt.785 Text en © 2017 The Authors Clinical Pharmacology & Therapeutics published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Development
Stewart, Clinton F.
Robinson, Giles W.
Development of Molecularly Targeted Therapies to Treat Pediatric Malignancies
title Development of Molecularly Targeted Therapies to Treat Pediatric Malignancies
title_full Development of Molecularly Targeted Therapies to Treat Pediatric Malignancies
title_fullStr Development of Molecularly Targeted Therapies to Treat Pediatric Malignancies
title_full_unstemmed Development of Molecularly Targeted Therapies to Treat Pediatric Malignancies
title_short Development of Molecularly Targeted Therapies to Treat Pediatric Malignancies
title_sort development of molecularly targeted therapies to treat pediatric malignancies
topic Development
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5656826/
https://www.ncbi.nlm.nih.gov/pubmed/28836264
http://dx.doi.org/10.1002/cpt.785
work_keys_str_mv AT stewartclintonf developmentofmolecularlytargetedtherapiestotreatpediatricmalignancies
AT robinsongilesw developmentofmolecularlytargetedtherapiestotreatpediatricmalignancies

Ejemplares similares